Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes

• Published in: International neurourology journal 2020, 24(1), , pp.21-28
• Main Authors: Choi, Jin Bong, Yoo, Je Mo, Lee, Ye-Jee, Kim, Jae Woong, Lee, Seung-Ju, Kim, Hee Youn, Lee, Dong Sup, Ko, Seung-Hyun, Choe, Hyun-Sop
• Format: Article
• Language: English
• Subjects: cytokines; dapagliflozin; diabetes mellitus; Original; urinary tract infection; 비뇨기과학
• ISSN: 2093-4777; 2093-6931; 2093-6931
• DOI: 10.5213/inj.1938220.110

To investigate the effect of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, on inflammatory cytokines of urogenital tissue in a rat model of type 2 diabetes (T2DM) to infer pharmaceutical influence of dapagliflozin on genitourinary infection or inflammation. Study animals were divided into the following 4 groups of 10 animals each: (1) the Otsuka Long-Evans Tokushima Fatty (OLETF)-DA group treated with dapagliflozin at 1.0 mg/kg/day, (2) the OLETF-VO group treated with voglibose at 0.6 mg/kg/day, (3) the control group (OLETF-CO) given water, and (4) the Long-Evans Tokushima Otsuka (LETO) rats were included as nondiabetic control group. Changes in blood glucose, 24-hour urine volume, and urine glucose were measured. The interleukin-1β (IL-1β) and interleukin-18 (IL-18) levels in the bladder and the urethra were quantified, respectively. The urine glucose level and the 24-hour urine volume at 12 weeks of treatment were significantly higher in the OLETF-DA group than that in any other group (P